Monday, February 16, 2026 2/16/2026

Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease

Award Number: R01AG088623
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease - ABSTRACT The development of biomarkers for Alzheimer’s disease resulted in the use of positron emission tomography (PET) and biofluid assays to detect AD pathology before clinical symptoms. However, these studies were conducted in predominantly non-Hispanic white populations to establish cut-off values for clinical trial recruitment, which have not translated well to Hispanic and African Americans (AA). The proposed project aims to comprehensively measure phosphorylated tau species p-tau217 in plasma from the Health and Aging Brain Study-Health Disparities (HABS-HD) study. We have previously demonstrated that combining p-tau217 with Aβ42/40 ratio and other AD covariates into predictive models resulted in detecting amyloid positivity at ≥ 20 Centiloids with 88% sensitivity and 90% specificity. We propose to leverage the HABS-HD cohort plasma samples to quantify plasma Aβ42/40 and p-tau217 levels in amyloid PET positive and negative in Hispanic and AA populations to determine cutoffs relevant to ethnicity and race. The overarching hypothesis of this project is that plasma biomarkers related to AD pathology present differently among diverse populations and as a result have different relations to established clinical outcomes such as PET amyloid levels and cognitive outcomes. To test this hypothesis, we propose to characterize plasma p-tau217 and Aβ42/40 in Mexican Americans, AA and non-Hispanic white populations of the HABS-HD study. Additionally, we propose to investigate how other AD hallmarks are associated with p-tau217 and Aβ42/40 in these individual populations. Resultant data will not only document the biomarker protein levels for the HABS-HD cohort for sharing in the longitudinal study but may also inform on whether amyloid PET scans can be reduced in the screening process.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $582,487 )
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Aging Research	001	2	9/4/2025	NON-COMPETING CONTINUATION	$47,549
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Aging Research	000	2	5/9/2025	NON-COMPETING CONTINUATION	$534,938
														Subtotal = $582,487

Issue Date FY: 2024 ( Subtotal = $594,041 )
2024	2024	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Aging Research	001	1	8/30/2024	NEW	$0
2024	2024	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Aging Research	000	1	8/22/2024	NEW	$594,041
														Subtotal = $594,041

Grand Total All Awards = $1,176,528

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease

Award Number: R01AG088623

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer